AAV2/TNFR:Fc: Phase I/II ongoing

Targeted Genetics completed dosing of 127 patients in a placebo-controlled, multi-dose Phase I/II trial of intra-articular tgAAC94. The study had been temporarily placed on hold last July after a pati...